17 results about "Hypertensive disease" patented technology

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

The invention belongs to the field of new traditional Chinese medicine development, and particularly relates to a traditional Chinese medicine composition composed of herba epimedii, uncaria, radix scrophulariae, rhizoma alismatis and radix cyathulae, an extraction method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition to treatment of blood pressure circadian rhythm disorder of hypertension. The pharmaceutical composition comprises the following raw material medicines: herba epimedii, uncaria, radix scrophulariae, rhizoma alismatis and radix cyathulae. The traditional Chinese medicine composition provided by the invention is suitable for hypertension disease blood pressure circadian rhythm disorder. According to the pathogenesis characteristics of hypertension, the invention provides the novel traditional Chinese medicine composition for treating blood pressure circadian rhythm disorder of hypertension and the preparation method thereof, and the compatibility effect of mutual promotion and mutual assistance is exerted according to the compatibility principle of monarch, minister, assistant and guide of traditional Chinese herbal medicines. The traditional Chinese medicine composition disclosed by the invention can effectively reduce systolic pressure and diastolic pressure of a hypertensive patient in 24 hours and control morning and night hypertension, and is high in safety. The traditional Chinese medicine composition provides a theoretical and clinical basis and a novel prescription strategy for clinically preventing and treating blood pressure circadian rhythm disorder of hypertension in traditional Chinese medicine.

This invention relates to the field of cardiovascular disease auxiliary diagnosis technology, specifically to a method and system for auxiliary diagnosis of high-altitude hypertension based on electrocardiogram (ECG). It uses 12-lead ECG images as input, constructs a multi-branch adaptive classification model that integrates regional priors, sequentially extracts shallow general features through a shared feature extraction module, combines independent feature branches from multiple leads with a paired spatial attention module to capture relative potential differences between leads, and a multi-path adaptive fusion module dynamically fuses differential features between high-altitude and plain areas using regional labels as gating signals. Finally, a hybrid classifier composed of capsule networks and DenseNet cascades the features to complete a four-class prediction: high-altitude hypertension, high-altitude normal, plain hypertension, and plain normal. This invention effectively overcomes the problem of cross-regional data domain shift, improves the ability to capture weak pathological features in ECG images, and has strong clinical transferability and robustness, making it suitable for auxiliary screening of hypertension across high-altitude and plain areas.

This invention belongs to the field of biomedical technology, specifically relating to the application of TLR1 receptor inhibitors in the preparation of products for treating hypertension. Existing drugs used clinically for hypertension have varying mechanisms of action. This study discovers a novel mechanism for treating hypertension: by inhibiting TLR1 receptors in juxtaglomerular cells of the kidney and hepatocytes of the liver, sympathetic nerve excitation-induced renin synthesis and glucocorticoid-induced angiotensinogen synthesis are suppressed, thereby inhibiting angiotensin II levels. This mechanism and method provide a new treatment option for hypertension, particularly neurogenic hypertension, and can also exhibit synergistic effects with existing therapeutic drugs. This invention identifies the TLR1 receptor as a novel target for treating hypertension. Currently, there are no developed and applied hypertension treatment drugs mediated by TLR1 receptors. This invention provides sufficient theoretical and experimental basis for the development of novel antihypertensive drugs.

The application belongs to the technical field of biological medicine, and relates to a mussel peptide and a preparation method and application thereof. The mussel peptide comprises one or more of the following peptide segments: (1) Ile-Leu-Thr-Glu-Arg (2) Leu-Asp-Leu-Ala-Gly-Arg (3) Val-Thr-Ile-Met-Pro-Lys (4) Met-Gln-Ile-Phe-Val-Lys (5) Leu-Phe-Asp-Ala-Val-Ile-Arg. The mussel peptide is prepared by adopting a complex enzyme-membrane separation-dextran gel column chromatography purification coupling technology. The peptide not only has the effect of relieving spontaneous hypertension, but also has the effect of improving various target organ damages caused by spontaneous hypertension. The application provides the possibility of application of the mussel peptide in improving various target organ damages caused by spontaneous hypertension or other diseases.

The application discloses a traditional Chinese medicine for treating hyperlipidemia and hypertension, which comprises an active ingredient, wherein the active ingredient is composed of the following components in parts by weight: American ginseng 6-14 parts, rhizoma polygonati 5-15 parts, fructus aurantii immaturus 9-15 parts, rhizoma atractylodis 18-60 parts, radix rehmanniae preparata 6-20 parts, prepared rhizome 15-60 parts, semen plantaginis 12-30 parts, earthworm 12-30 parts, hawthorn 15-60 parts, white mulberry root-bark 12-30 parts, and prunella vulgaris 20-80 parts; compared with the prior art, the application takes natural plants, American ginseng and prunella vulgaris, as the core components, and is composed of various traditional Chinese medicines for benefiting qi and invigorating the spleen, dredging bowels and resolving turbidity, so that the traditional Chinese medicine has the effects of invigorating the spleen, benefiting qi, dredging bowels and resolving turbidity; through organic matching of the medicines, three metabolisms are regulated, hyperlipidemia is reduced, the vascular intima is protected, blood lipid deposition in the vascular intima is reduced, the myocardial blood supply is improved, diuresis is achieved, the tension degree of blood vessels is relieved, and the like, so that the utility of improving clinical syndromes is achieved; the safety and effectiveness of the traditional Chinese medicine have been verified through clinical research, and the traditional Chinese medicine has good practical clinical application value.

The application discloses a traditional Chinese medicine formula for treating hypertension and a preparation method thereof, and belongs to the technical field of formula preparation of hypertension and comprises the following raw materials in parts by weight: 5-15 parts of rhubarb, 5-15 parts of dried ginger, 5-15 parts of oyster shell, 5-15 parts of oyster, 5-15 parts of cassia twig, 5-15 parts of white peony root, 5-15 parts of prepared rehmannia root and 5-15 parts of mountain yam. In the application, the core compatibility of Feng Yin decoction, Liuwei Dihuang decoction, Taohong Siwu decoction and Huanglian Jiedu decoction is fused, the five effects of 'calming liver and suppressing yang, nourishing yin and kidney, promoting blood circulation and removing blood stasis, clearing heat and resolving toxin and invigorating spleen and stomach' are considered, the pathogenesis of 'deficiency in origin and excess in superficiality' of hypertension is adjusted as a whole, compared with existing western medicines, the drug has stable and long-acting effect, can effectively reduce blood pressure, can significantly improve dizziness, headache, chest distress and other accompanying symptoms, can reduce the dependence of patients on chemical antihypertensive drugs and side effects such as liver and kidney damage and electrolyte disturbance caused by the chemical antihypertensive drugs, and is especially suitable for long-term taking of middle-aged and old patients and patients with combined basic diseases.

The invention discloses a neural feedback system and method for adjuvant therapy of hypertension, and aims to solve the problems that hypertension intervention depends on long-term drug maintenance and is poor in behavior intervention compliance, and existing neural feedback equipment lacks closed-loop integration for pathophysiological mechanisms of hypertension. According to the method and the system, the low-frequency breathing rhythm is set by providing focused breathing guidance, the electroencephalogram signals of the frontal midline area of the user are collected in real time, the Theta rhythm power is extracted, the audio-visual multi-mode feedback signals which gradually change along with the enhancement of the Theta rhythm power are generated, and behavior-nerve synchronous closed-loop training is formed, so that the autonomic nervous system regulation ability of the user is enhanced. According to the method, precise targeted pressure reduction can be achieved, the training threshold is lowered, the user compliance is improved, and noninvasive safety is achieved. The system can be used as an independent digital therapy tool, can also be used in combination with drug therapy, and provides a new choice of non-drug intervention for hypertension management.

The utility model discloses a monitoring device for an intake salt meter of a hypertensive patient, and relates to the technical field of biological substances such as blood and urine. The monitoring device comprises a display, the right side of the display is fixedly connected with a fixing block, the right side of the fixing block is provided with a storage groove, the left side of the storage groove penetrates through the fixing block, a supporting plate is installed in the storage groove, and the upper side and the lower side of the supporting plate are both semi-cylindrical surfaces. A storage groove is formed in the upper portion of the fixing block, a check block is connected into the storage groove, the left side of the check block is fixedly connected with the displayer, the check block is arranged at the position close to the lower side, the right side of the displayer is fixedly connected with a containing shell, and a control mechanism is arranged in the fixing block. And therefore, the display can be supported and fixed on different objects, and meanwhile, the stability after supporting can be ensured, so that the application range of the device is widened.

The application relates to an attention mechanism-based fundus color photograph processing device, which comprises an image preprocessing module, a blood vessel feature extraction module and a convolutional neural network module; wherein the image preprocessing module comprises a mask extraction module and an image enhancement module; the mask extraction module is used for extracting a mask, and the mask is used for segmenting an image of a region of interest and an image of a non-region of interest in a fundus color photograph; the image enhancement module is used for performing contrast enhancement on the fundus color photograph; the image preprocessing module performs clipping on the fundus color photograph by using the mask to obtain a preprocessed fundus color photograph image; the blood vessel feature extraction module extracts a blood vessel distribution saliency map according to the preprocessed fundus color photograph image; the blood vessel distribution saliency map and the preprocessed fundus color photograph image are multiplied after point-to-point activation of each color channel to serve as input of the convolutional neural network module; and the convolutional neural network model focuses on learning an image region related to a hypertension symptom.

The present invention relates to novel sublingual compositions comprising an anti-fibrotic agent, as well as methods for their preparation. Wherein the composition comprising an anti- fibrotic agent such as pirfenidone or nintedanib and its analogs or pharmaceutically acceptable salts thereof. These novel sublingual compositions are intended for use in the treatment of fibrotic diseases, disorders, or conditions, such as idiopathic pulmonary fibrosis (IPF), and hypertensive diseases, disorders, or conditions such as pulmonary hypertension.

Use of a composition in preparation of a drug for treating a patient suffering from a cerebral stroke. The composition includes edaravone and dexborneol, and the patient has a history of hypertension.

The invention discloses an OCTA-based hypertension and small vascular disease recognition model and system, and belongs to the technical field of medical image recognition, and the method comprises the steps: collecting an OCTA image, combining the vascular structure features and nerve and blood vessel features of different retina regions, synchronously researching the correlation between retina key parameters and the pathological state of hypertension and the pathological state of small vascular diseases, and carrying out the recognition of the hypertension and small vascular diseases. A set of complete framework from OCTA imaging parameter optimization, retina image acquisition and feature extraction to hypertension diagnosis, small vascular disease diagnosis and system capillary burden index construction is established. The invention provides an efficient and intelligent solution for collaborative screening of hypertension and small vascular diseases, and has important significance for improving the knowing rate and the control rate of hypertension and small vascular diseases in China and reducing the burden of cardiovascular diseases.

The application discloses an immunogenic short peptide of angiotensin II receptor type 1 and application thereof, wherein the amino acid sequence of the immunogenic short peptide is shown as SEQ ID No. 1: AFHYE. An effective component of the immunogenic carrier vaccine is a coupling product of the immunogenic short peptide and a carrier. The application couples the immunogenic short peptide with a Qbeta carrier to obtain an effective component of the vaccine of the immunogenic peptide segment of angiotensin II receptor type 1. The effective component is used for preparing the immunogenic carrier vaccine for antihypertensive treatment of primary hypertension, can be used as a long-acting antihypertensive drug, and is helpful to improving the compliance of the primary hypertension patients in treatment, thereby achieving the purpose of effectively controlling blood pressure.

The invention relates to the field of medicine and health care, in particular to a composition as well as a preparation method and application thereof. The composition provided by the invention is prepared from the following raw materials in parts by weight: 5-18 parts of poria cocos, 5-15 parts of semen cassiae, 5-15 parts of fructus lycii, 3-9 parts of spica prunellae, 5-15 parts of pericarpium citri reticulatae and 10-30 parts of corn stigma. The traditional Chinese medicine composition comprises poria cocos, semen cassiae, fructus lycii, spica prunellae, pericarpium citri reticulatae and corn stigma, and has the effects of removing heat from the liver, reducing phlegm, invigorating the spleen and tonifying the kidney. The composition can be used for safely and effectively reducing the consulting room blood pressure of critical hypertension people, reducing the prevalence rate of hypertension, slowing down the progression of critical hypertension to clinical diseases, reducing the medical cost as much as possible, and relieving the economic burden of patients.

The invention discloses an over-conversion module of an eye fundus image and an interpretation system comprising the over-conversion module. The excessive conversion module is used for converting the first judgment result of the fundus image of which the first judgment result is a negative result into a positive result so as to be matched with the requirement of a preset negative prediction rate or setting the first judgment result of the fundus image meeting a preset condition as the positive result; the first judgment result is a result obtained by judging the eye fundus image based on a machine learning method; the preset conditions comprise at least one of the conditions that the fundus disease history exists, the corrected vision is lower than the preset vision, the history of diabetes mellitus or the course of diabetes mellitus is greater than or equal to a first preset age limit, the history of hypertension or the course of hypertension is greater than or equal to a second preset age limit, and the recent vision decline. Therefore, the accuracy of interpreting fundus anomalies in the fundus image can be improved.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).